Aberdeen Group plc Has $29.34 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT

Aberdeen Group plc boosted its position in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 101.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,605,984 shares of the company’s stock after purchasing an additional 809,182 shares during the quarter. Aberdeen Group plc owned about 1.94% of Eyepoint Pharmaceuticals worth $29,341,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Jefferies Financial Group Inc. bought a new stake in Eyepoint Pharmaceuticals during the 3rd quarter worth $1,994,000. Corient Private Wealth LLC bought a new position in Eyepoint Pharmaceuticals in the second quarter valued at about $1,200,000. Walleye Capital LLC boosted its stake in shares of Eyepoint Pharmaceuticals by 500.6% during the second quarter. Walleye Capital LLC now owns 199,449 shares of the company’s stock valued at $1,877,000 after purchasing an additional 166,243 shares in the last quarter. Rosalind Advisors Inc. acquired a new stake in shares of Eyepoint Pharmaceuticals during the third quarter valued at about $9,256,000. Finally, Stempoint Capital LP bought a new stake in shares of Eyepoint Pharmaceuticals during the second quarter worth about $3,098,000. 99.41% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Citigroup upped their price objective on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, March 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Thursday, January 22nd. HC Wainwright upped their price target on Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. TD Cowen raised shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research note on Friday, December 19th. Finally, Chardan Capital upped their price target on shares of Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $32.20.

Eyepoint Pharmaceuticals Price Performance

NASDAQ:EYPT opened at $13.40 on Monday. The firm has a market capitalization of $1.12 billion, a P/E ratio of -4.24 and a beta of 1.89. The company has a fifty day moving average of $14.42 and a 200-day moving average of $14.52. Eyepoint Pharmaceuticals, Inc. has a twelve month low of $3.91 and a twelve month high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Wednesday, March 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.03). The company had revenue of $0.62 million for the quarter, compared to the consensus estimate of $1.01 million. Eyepoint Pharmaceuticals had a negative return on equity of 88.31% and a negative net margin of 739.39%. On average, analysts anticipate that Eyepoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.